OnCURE Medical Corp. Names Vincent S. Pino As Senior Vice President and Chief Development Officer
OnCURE Medical Corp. (“OnCURE”), a leading provider of outpatient radiation therapy services, today announced the appointment of Vincent S. Pino to the new position of Senior Vice President and Chief Development Officer.
Richard Zehner, OnCURE’s Chief Executive Officer, stated, “We are very pleased that an executive with Vince’s skills and experience has joined OnCURE. He has a proven track record in helping companies to grow rapidly and he now joins our company at a very exciting time. With the added support of our new investors at Genstar, we have the ability to strategically grow our operations both organically and through geographic expansion. Vince’s ability to structure, negotiate and integrate acquisitions will add tremendous value as we move forward with our growth plan.”
From 1988 until 2001, Mr. Pino held various executive positions with Alliance Imaging, Inc. including President; Executive Vice President and Chief Operating Officer; Executive Vice President and Chief Financial Officer; as well as Director. Mr. Pino was instrumental in building Alliance into the largest publicly-held diagnostic imaging company. He has extensive background in acquisitions, operations, financings, and investor relations. Prior to joining Alliance, Mr. Pino held several executive positions including Executive Vice President and Vice President of Corporate Planning with Petrolane, Inc., a large diversified publicly-held services company with over $1 billion in revenues. In 2003, Mr. Pino co-founded and currently serves as Chairman of Center Pointe Sleep Associates LLC, an operator of six sleep diagnostic labs in Pennsylvania, Ohio and West Virginia. He is also a director of Insignia Solutions, plc, a publicly-held software developer. Mr. Pino holds an MBA in Finance and a BS in Finance from the University of Southern California.
“I am very pleased to join an organization that has the commitment and focus to patient care as OnCURE,” said Mr. Pino. “As we move forward with our growth plans it will be imperative that we seamlessly integrate our operations in order to provide superior patient service throughout all of our facilities.”
About OnCURE
OnCURE Medical Corp., a portfolio company of Genstar Capital LLC, owns, operates and manages 33 radiation centers and other mobile HDR & PET/CT units, all located in California and Florida. OnCURE’s centers provide treatment areas and equipment for radiation therapy and diagnostic radiology, including IMRT, CT and PET. OnCURE provides capital, technology, and management expertise to its affiliated physician groups (approximately 55 doctors), including clinical management, billing and collection, data warehousing, accounting, compliance and other administrative services. OnCURE has approximately 350 employees. For more information, visit www.OnCURE.com.
About Genstar Capital, LLC
Based in San Francisco, Genstar Capital (www.gencap.com) is a private equity investment firm that makes leveraged investments in quality middle-market companies. Genstar Capital works in partnership with management to transform its portfolio companies into industry-leading businesses. With more than $900 million of committed capital under management and significant experience investing in businesses, Genstar focuses on selected segments of the health care services, life sciences, business services, and industrial technology sectors.
Forward-Looking Statements
Statements in this Press Release that are not historical facts constitute “forward-looking statements.” Any statements contained herein which are not historical facts or which contain the words “anticipate,”"believe,”"continue,”"estimate,”"expect,”"intend,”"may,”"should,” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current view of OnCURE with respect to future events and are subject to certain risks, uncertainties and assumptions, including, but not limited to, the risk that OnCURE may not be able to implement its growth strategy in the intended manner, including the ability to identify, finance, complete and integrate acquisitions and joint venture opportunities, risks regarding currently unforeseen competitive pressures and risks affecting OnCURE’s industry, such as increased regulatory compliance and changes in regulatory requirements, changes in payor reimbursement levels and the development of additional alternative treatment modalities and technological changes. Should one or more of those risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein.